Roman Ivasiy
Biographic Data
| ID | 3074840 |
|---|---|
| NAME | Roman Ivasiy |
| GIVEN NAMES | Roman |
| FAMILY NAME | Ivasiy |
| SIGNATURE | IVASIY R |
| AFFILIATIONS | Yale University |
| ORCID | 0000-0002-8405-1360 |
| VERIFIED | Yes |
| TOTAL WORKS | 9 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 9 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
HIV-Stigmatizing Beliefs and Attitudes as a Barrier to Early PrEP Care Continuum Engagement Among People Who Inject Drugs
HIV pre-exposure prophylaxis (PrEP) is a highly effective prevention strategy, yet awareness, knowledge, and willingness to use it among people who inject drugs (PWID) remains inadequate despite widespread eligibility. Stigma, particularly HIV-stigmatizing beliefs and attitudes, may be a key barrier to engagement at early stages of the PrEP care continuum. We examine how HIV-stigmatizing beliefs and attitudes affect PrEP awareness, knowledge, and…
Development and Validation of a Provider-Specific Anticipated Stigma Scale for People Who Inject Drugs
Stigma in healthcare settings is a critical barrier to HIV prevention and treatment among people who inject drugs (PWID). While previous tools have measured anticipated stigma, few account for the intersectional and provider-specific experiences of PWID-particularly from syringe service programs (SSPs). We developed and validated the Substance Use Anticipated Provider Stigma Scale (SU-APSS), a multidimensional instrument assessing anticipated sti…
Combined response to commentaries regarding Ivasiy et al. (2025)
Retention and dropout from sublingual and extended-release buprenorphine treatment
Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine
Stalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan
HIV incidence and mortality are increasing in Eastern Europe and Central Asia and are concentrated in people who inject drugs. Maintenance with opioid agonist therapies (OAT) like methadone or buprenorphine is the best treatment for opioid use disorder and a key HIV-prevention strategy in the region. In Kazakhstan, the scale-up of methadone has been minimal since methadone’s introduction in 2008 and has been supported through international charit…
Early disruptions to syringe services programs during the Russian invasion of Ukraine
Introduction: The widespread HIV epidemic in Ukraine is concentrated among people who inject drugs (PWID), making access to sterile injection paraphernalia (SIP) like sterile needles and syringes a critical method of HIV/AIDS prevention; however, the Russian invasion has threatened to disrupt the operations of syringe services programs (SSPs), creating a risk of HIV outbreaks among PWID. Methods: We conducted 10 semi-structured interviews with ou…
Responding to health policy recommendations on managing opioid use disorder during Russia's invasion of Ukraine
Russia's invasion of Ukraine on February 24, 2022, followed by Ukraine's Martial law, has disrupted the routine delivery of healthcare services, including opioid agonist treatment (OAT) programs. Directors (chief addiction treatment physicians) of these programs in each region had flexibility with implementing a series of adaptations to their practice to respond to war disruptions like mass internal displacement and legislation updates allowing m…
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the Covid-19 pandemic in Ukraine
Background: The COVID-19 pandemic resulted in marked disruptions in healthcare delivery in Ukraine related to emergency guidance in response to treating opioid use disorder (OUD). Patients with OUD, a group with high levels of comorbid medical and psychiatric disorders, and prescribed opioid agonist therapies (OAT) were rapidly shifted to take-home dosing if they were deemed clinically stable. The impact of these shifts on patient stress and rela…
No prominent works on this page.
Early disruptions to syringe services programs during the Russian invasion of Ukraine
Introduction: The widespread HIV epidemic in Ukraine is concentrated among people who inject drugs (PWID), making access to sterile injection paraphernalia (SIP) like sterile needles and syringes a critical method of HIV/AIDS prevention; however, the Russian invasion has threatened to disrupt the operations of syringe services programs (SSPs), creating a risk of HIV outbreaks among PWID. Methods: We conducted 10 semi-structured interviews with ou…
Responding to health policy recommendations on managing opioid use disorder during Russia's invasion of Ukraine
Russia's invasion of Ukraine on February 24, 2022, followed by Ukraine's Martial law, has disrupted the routine delivery of healthcare services, including opioid agonist treatment (OAT) programs. Directors (chief addiction treatment physicians) of these programs in each region had flexibility with implementing a series of adaptations to their practice to respond to war disruptions like mass internal displacement and legislation updates allowing m…
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the Covid-19 pandemic in Ukraine
Background: The COVID-19 pandemic resulted in marked disruptions in healthcare delivery in Ukraine related to emergency guidance in response to treating opioid use disorder (OUD). Patients with OUD, a group with high levels of comorbid medical and psychiatric disorders, and prescribed opioid agonist therapies (OAT) were rapidly shifted to take-home dosing if they were deemed clinically stable. The impact of these shifts on patient stress and rela…
Stalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan
HIV incidence and mortality are increasing in Eastern Europe and Central Asia and are concentrated in people who inject drugs. Maintenance with opioid agonist therapies (OAT) like methadone or buprenorphine is the best treatment for opioid use disorder and a key HIV-prevention strategy in the region. In Kazakhstan, the scale-up of methadone has been minimal since methadone’s introduction in 2008 and has been supported through international charit…
Combined response to commentaries regarding Ivasiy et al. (2025)
Retention and dropout from sublingual and extended-release buprenorphine treatment
Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine
HIV-Stigmatizing Beliefs and Attitudes as a Barrier to Early PrEP Care Continuum Engagement Among People Who Inject Drugs
HIV pre-exposure prophylaxis (PrEP) is a highly effective prevention strategy, yet awareness, knowledge, and willingness to use it among people who inject drugs (PWID) remains inadequate despite widespread eligibility. Stigma, particularly HIV-stigmatizing beliefs and attitudes, may be a key barrier to engagement at early stages of the PrEP care continuum. We examine how HIV-stigmatizing beliefs and attitudes affect PrEP awareness, knowledge, and…
Development and Validation of a Provider-Specific Anticipated Stigma Scale for People Who Inject Drugs
Stigma in healthcare settings is a critical barrier to HIV prevention and treatment among people who inject drugs (PWID). While previous tools have measured anticipated stigma, few account for the intersectional and provider-specific experiences of PWID-particularly from syringe service programs (SSPs). We developed and validated the Substance Use Anticipated Provider Stigma Scale (SU-APSS), a multidimensional instrument assessing anticipated sti…
Opioid Use Disorder Treatment (7 works) · HIV, Drug Use, Sexual Risk (6 works) · Medicine (6 works) · Psychiatry (4 works) · Psychology (4 works) · Family medicine (3 works) · Health care (3 works) · HIV/AIDS Research and Interventions (3 works) · Opioid (3 works) · Buprenorphine (2 works)